Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) EBT (2016 - 2025)

Historic EBT for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $15.2 million.

  • Corcept Therapeutics' EBT fell 7120.87% to $15.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $88.5 million, marking a year-over-year decrease of 4678.82%. This contributed to the annual value of $161.5 million for FY2024, which is 2965.39% up from last year.
  • Per Corcept Therapeutics' latest filing, its EBT stood at $15.2 million for Q3 2025, which was down 7120.87% from $31.7 million recorded in Q2 2025.
  • In the past 5 years, Corcept Therapeutics' EBT registered a high of $52.9 million during Q3 2024, and its lowest value of $9.6 million during Q1 2025.
  • In the last 5 years, Corcept Therapeutics' EBT had a median value of $32.1 million in 2022 and averaged $30.7 million.
  • Its EBT has fluctuated over the past 5 years, first surged by 8982.86% in 2024, then crashed by 7251.45% in 2025.
  • Corcept Therapeutics' EBT (Quarter) stood at $36.7 million in 2021, then plummeted by 33.92% to $24.3 million in 2022, then skyrocketed by 51.63% to $36.8 million in 2023, then decreased by 13.17% to $32.0 million in 2024, then plummeted by 52.31% to $15.2 million in 2025.
  • Its EBT was $15.2 million in Q3 2025, compared to $31.7 million in Q2 2025 and $9.6 million in Q1 2025.